Tyler Stone Wealth Management Raises Position in Kenvue Inc. (NYSE:KVUE)

Tyler Stone Wealth Management grew its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 134.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 49,050 shares of the company's stock after purchasing an additional 28,125 shares during the period. Tyler Stone Wealth Management's holdings in Kenvue were worth $1,135,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lorne Steinberg Wealth Management Inc. increased its holdings in Kenvue by 59.0% during the 2nd quarter. Lorne Steinberg Wealth Management Inc. now owns 154,690 shares of the company's stock worth $2,812,000 after purchasing an additional 57,375 shares in the last quarter. Kennon Green & Company LLC grew its holdings in shares of Kenvue by 140.7% in the second quarter. Kennon Green & Company LLC now owns 159,106 shares of the company's stock valued at $2,893,000 after acquiring an additional 93,008 shares in the last quarter. Czech National Bank grew its holdings in shares of Kenvue by 20.3% in the second quarter. Czech National Bank now owns 364,886 shares of the company's stock valued at $6,634,000 after acquiring an additional 61,635 shares in the last quarter. Crestwood Advisors Group LLC grew its holdings in shares of Kenvue by 14.8% in the second quarter. Crestwood Advisors Group LLC now owns 1,537,348 shares of the company's stock valued at $27,950,000 after acquiring an additional 198,607 shares in the last quarter. Finally, Clearbridge Investments LLC grew its holdings in shares of Kenvue by 16,051.1% in the first quarter. Clearbridge Investments LLC now owns 9,813,597 shares of the company's stock valued at $210,600,000 after acquiring an additional 9,752,836 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.71 during trading on Friday, hitting $23.68. 16,635,437 shares of the company were exchanged, compared to its average volume of 16,248,485. The company has a market cap of $45.35 billion, a PE ratio of 40.83, a P/E/G ratio of 2.94 and a beta of 1.36. The stock has a 50 day moving average of $22.65 and a 200 day moving average of $20.54. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $23.72. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business's quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.31 earnings per share. As a group, equities research analysts predict that Kenvue Inc. will post 1.08 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be given a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.46%. Kenvue's dividend payout ratio (DPR) is presently 141.38%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on KVUE shares. Jefferies Financial Group started coverage on Kenvue in a report on Tuesday, September 24th. They issued a "buy" rating and a $27.00 target price for the company. Deutsche Bank Aktiengesellschaft upped their target price on Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. upped their price objective on Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, October 11th. Royal Bank of Canada downgraded Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective on the stock. in a research note on Tuesday, September 24th. Finally, UBS Group upped their price objective on Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.